PATENT CLAIM ANALYSIS

Application Number: 15982449
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "220000"]

Abstract:
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Claim (Index 18):
The method of  claim 17 , wherein the pharmaceutical dosage form comprises about 300 mg of olanzapine or a pharmaceutically acceptable salt thereof that is equivalent to about 300 mg of olanzapine.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15926076', '11274887', '14773642', '15101874', '14995658']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7696662555857307
- 35 USC 102 Novelty (BERT): 0.5787828515063919
- Combined Prediction Score: 0.7505779151777968
- Mean Citation Score: 251.3072200000001
- Max Citation Score: 481.5187
- Similarity Product: 390.90127334439165

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test